Form 8-K - Current report:
SEC Accession No. 0000875045-22-000013
Filing Date
2022-05-03
Accepted
2022-05-03 07:11:33
Documents
15
Period of Report
2022-05-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K biib-20220503.htm   iXBRL 8-K 33903
2 EX-10.1 exhibit101letteragreement.htm EX-10.1 24119
3 EX-99.1 exhibit991-q12022pressrele.htm EX-99.1 348085
7 biogenlogostandarda29.jpg GRAPHIC 756402
  Complete submission text file 0000875045-22-000013.txt   1606491

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT biib-20220503.xsd EX-101.SCH 1933
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT biib-20220503_lab.xml EX-101.LAB 24275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT biib-20220503_pre.xml EX-101.PRE 12662
9 EXTRACTED XBRL INSTANCE DOCUMENT biib-20220503_htm.xml XML 10549
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 22884572
SIC: 2836 Biological Products, (No Diagnostic Substances)